Polyarteritis nodosa is a progressive, often life-threatening, vasculitis affecting multiple organs, including the skin and peripheral nerves. We report a patient presenting with systemic features of the disease and with characteristic lesions in the feet 3 weeks after vaccination against hepatitis B virus infection.
There are no randomized clinical trials on efficacy of Entecavir in Fulminant Hepatic Failure (FHF) due to Hepatitis B Virus (HBV). Definitive treatment of FHF remains Liver Transplant. However, availability of cadaveric donor organs is limited, and many of the patients with FHF may not be candidates for Liver Transplantation. There are only few case reports on beneficial effects of Entecavir in FHF due to HBV. We present 2 cases of FHF due to HBV. Both patients had severe liver cell damage among which one was immunocompromised. Transaminases were elevated up to 200 times the normal. Both were not transplant candidates, and were successfully treated with Entecavir resulting in significant clinical and transaminases improvement within 7 days of starting Entecavir. DOI: http://dx.doi.org/10.3126/jaim.v2i2.8780 Journal of Advances in Internal Medicine 2013;02(02):67-70
Hepatotropic Viral Infection Associated Systemic Vasculitides—Hepatitis B Virus Associated Polyarteritis Nodosa and Hepatitis C Virus Associated Cryoglobulinemic Vasculitis